Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Net Margin (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Net Margin for 8 consecutive years, with 404.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 27230.0% year-over-year to 404.1%, compared with a TTM value of 80.19% through Dec 2025, down 2705.0%, and an annual FY2025 reading of 80.19%, down 2705.0% over the prior year.
  • Net Margin was 404.1% for Q4 2025 at Arcturus Therapeutics Holdings, down from 78.4% in the prior quarter.
  • Across five years, Net Margin topped out at 74.02% in Q4 2022 and bottomed at 2711.14% in Q1 2021.
  • Average Net Margin over 5 years is 541.37%, with a median of 79.0% recorded in 2022.
  • The sharpest move saw Net Margin crashed -235355bps in 2021, then surged 260507bps in 2022.
  • Year by year, Net Margin stood at 649.72% in 2021, then soared by 111bps to 74.02% in 2022, then tumbled by -151bps to 37.85% in 2023, then plummeted by -248bps to 131.8% in 2024, then crashed by -207bps to 404.1% in 2025.
  • Business Quant data shows Net Margin for ARCT at 404.1% in Q4 2025, 78.4% in Q3 2025, and 32.44% in Q2 2025.